Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
03 avr. 2024 06h43 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a...
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
22 mars 2024 04h00 HE
|
Molecure
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the...
Alvotech heldur uppgjörsfund fyrir árið 2023 í beinu streymi þann 21. mars nk. kl. 12:00 að íslenskum tíma
05 mars 2024 16h01 HE
|
Alvotech
Fjárfestadagur, sem einnig verður sendur út á vefnum, verður haldinn föstudaginn 22. mars nk. Alvotech (NASDAQ: ALVO) birtir ársuppgjör fyrir 2023 að kvöldi miðvikudagsins 20. mars nk., eftir lokun...
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
05 mars 2024 16h01 HE
|
Alvotech
Alvotech to host Capital Markets Day in Reykjavik and on-line on March 22, 2024 Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar...
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
04 mars 2024 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech Appoints Interim Chief Quality Officer
29 févr. 2024 16h05 HE
|
Alvotech
REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Cybrexa Regains Rights to CBX-12
06 févr. 2024 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
29 janv. 2024 04h00 HE
|
Alvotech
The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpoints Prolia® and Xgeva® (denosumab) are indicated...
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
19 janv. 2024 11h30 HE
|
Alvotech
REYKJAVIK, Iceland, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
03 janv. 2024 03h30 HE
|
Alvotech
The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular...